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Letter to the editor on “Potential use of salt substitutes to reduce blood pressure” 1 
Dear Editor,  2 
Farrand et al 1 have provided a convincing argument about the potential opportunities for 3 
inclusion of salt substitutes in staple foods to increase potassium intake and reduce blood 4 
pressure. We wish to offer an alternative viewpoint on this topic as specialist dietitians who 5 
work with adults with end stage kidney disease. 6 
 7 
First, we believe the number of people who may be at risk of adverse events from increased 8 
potassium consumption has been understated and the magnitude of the effect of including 9 
potassium salts overstated. In the Chronic Kidney Disease (CKD) population, prevalence of 10 
hyperkalemia is estimated to be as high as 14% to 20% 2.  In the general practice setting the 11 
incidence of clinically significant hyperkalaemia among Australian adults with CKD who 12 
were prescribed a renin-angiotensin-aldosterone system inhibitor has been estimated at 9.9% 13 
3. Data from the United Kingdom was strikingly similar 4.  These numbers are not 14 
insignificant and the widespread inclusion of salt substitutes in staple foods could increase 15 
the incidence of hyperkalaemia in the population. Furthermore, evidence from the cluster 16 
RCT in rural China where potassium salts were provided to 60 villages produced statistically 17 
but not clinically significant reductions in sodium intake (mean reduction of sodium intake 18 
was 14 mmol per day)5. There is also emerging evidence that salt reduction strategies are 19 
most effective when targeted to those in the highest quartile of intake and not the general 20 
population 6. 21 
 22 
Second, the statement by the authors that ‘use of salt substitutes as a public health 23 
intervention warrants consideration as part of policy recommendations’ is of great concern to 24 
3 
 
us. Salt substitutes are one potential public health intervention to reduce sodium intake and 1 
increase potassium intake. Improving overall diet quality could be a more cost effective 2 
strategy. Dietary patterns high in fruit, vegetables, wholegrain cereals, legumes, nuts, seeds 3 
and fish reduce systolic BP by 4.26 mm Hg and diastolic BP by 2.38 mm Hg 7. This exceeds 4 
the benefits of the salt substitutes quoted. 5 
 6 
We strongly suggest that it is premature to include salt substitutes in the food supply at a 7 
population level until adequate changes in food labelling and education campaigns are in 8 
place. Potassium is already a voluntary inclusion on food labels in the United States, but in 9 
places such as Australia, New Zealand and the UK it is not. The importance of this inclusion 10 
cannot be underestimated. Recommendations to follow a low potassium diet become 11 
infinitely more difficult for these at risk populations when salt substitutes are included in 12 
staple foods such as breads and cereals (which are not traditionally high in potassium). 13 
Furthermore, there are concerns that similar to phosphate additives potassium additives are 14 
more bioavailable than naturally occurring potassium in foods.  Potassium bioavailability from 15 
food additives may be as high as 90-100% compared to that of 50-60% of potassium found in 16 
fruit and vegetables 8. We recommend that inclusion of salt substitutes into the food supply 17 
should be accompanied by monitoring of hospital admissions for hyperkalaemia especially in 18 
‘susceptible’ groups. Furthermore, warning labels for salt substitutes should be strengthened 19 
and care taken to ensure clinicians and consumers are aware of the high bioavailability and how to 20 
identify potassium additives to avoid causing hyperkalemia. Inappropriate use of salt substitutes at 21 
the table to vulnerable groups can prove fatal. For example, 1/8th of a teaspoon of a salt 22 
substitute will typically provide around 350mg or 10 mmol of potassium. This far exceeds the 23 
allowable amount of potassium in medications of 100 mg by the US FDA and is required to 24 
be accompanied by a warning 9.  25 
4 
 
In the present era of patient centred medicine, consideration should be given to also including 1 
the patient perspective regarding discussions about the inclusion of potentially fatal salt 2 
substitutes into the food supply. 3 
 4 
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